PROYECTOS CONVOCATORIA PÚBLICA

Projet PI16/00002

HVEM / BTLA / CD160 Y PD-L1/PD1 como dianas inmunoterapéuticas en el tratamiento de tumores hematopoyéticos

Financeur: INSTITUTO DE SALUD CARLOS III (ISCIII)

Durée de 02 avril 2019 à 30 septembre 2020 (18 mois) Fini

23 740,70 EUR

Sphère National.

Annonce: (INSTITUTO DE SALUD CARLOS III (ISCIII))

Chercheurs

Foto de Mª LUISA DEL

Responsable

Foto de JOSE IGNACIO

RODRÍGUEZ BARBOSA

Publications liées au projet

Montrer par typologie

2024

Assesment of Hypoderma infestation in a wild population of Cervus elaphus from mountains Atlantic ecosystems in southwestern Europe (Spain)
Veterinary Research Communications

2023

Genetic deletion of HVEM in a leukemia B cell line promotes a preferential increase of PD-1- stem cell-like T cells over PD-1+ T cells curbing tumor progression
Frontiers in Immunology

2022

The impact of CD160 deficiency on alloreactive CD8 T cell responses and allograft rejection
Translational Research
Differential Engraftment of Parental A20 PD-L1 WT and PD-L1 KO Leukemia Cells in Semiallogeneic Recipients in the Context of PD-L1/PD-1 Interaction and NK Cell-Mediated Hybrid Resistance
Frontiers in Immunology

2020

Critical role of PD-L1 expression on non-tumor cells rather than on tumor cells for effective anti-PD-L1 immunotherapy in a transplantable mouse hematopoietic tumor model
Cancer Immunology, Immunotherapy